Film-for-IMAX Strategy Delivers Step-Change Indexing (15% Opening Weekend on <1% of Screens, 20%+ on 3 of 7 FFI Titles This Summer); Q2 Box Office +41%, Installs +50%, EBITDA Margin 42.6% (Record); Revolver Expanded to $375M Through 2030 De-Risks the $230M April-2026 Convert; FY25 Install Guide Raised to 150-160 — Initiating Coverage at Outperform

Results vs. Consensus — Q2 2025

Q2 Scorecard

YoY Comparison

Quality-of-Beat Callout

Segment Performance

Content Solutions ($34M revenue / 66% gross margin)

Content Solutions is the segment most directly leveraged to global box-office performance — it captures the studio-paid revenue from IMAX remastering, distribution, and the marketing premium on FFI titles. The 49% YoY box-office growth flowed almost directly to a 66% gross margin (+2,000bp YoY), reflecting the inherent incrementality: once a film is remastered for IMAX, every additional dollar of global box office above the production cost recovery line falls through at very high rates. Q2's 5.3% domestic market share and 6.0% China market share on less than 1% of global screens is the structural indexing achievement.

Assessment: Content Solutions is the operating-leverage engine of the IMAX model. Each FFI title raises the indexing floor for the network as a whole; each successful local-language release (Demon Slayer in Japan; the upcoming Don J Rescue in China) extends the addressable content pool beyond Hollywood. The 66% gross margin in Q2 is not a peak — it is a base rate that the business is increasingly capable of holding through the cycle. The slate visibility through 2028 (the 2026 slate is "almost all filled up"; the 2027 slate has at least 8 confirmed FFI titles) means Content Solutions has multi-year visibility on its top line that the rest of premium cinema simply does not have.

Technology Products & Services ($56M revenue / 54% gross margin)

Tech Products & Services captures the system-sale revenue, system-rental revenue (under joint revenue-sharing arrangements), and maintenance revenue across the global network. Revenue +9% YoY to $56M reflects the 36-install quarter and a mix shift toward sales-type arrangements, including 8 systems that were both signed and installed in Q2 — an unusually fast sign-to-install cycle that speaks to exhibitor urgency. Gross margin 54% (+360bp YoY) reflects scale leverage on the maintenance base and the higher mix of sales-type installs.

Assessment: Tech P&S is the network-expansion lever. The 124-system signing pace through 1H is the leading indicator of multi-year installation growth; the 131-system domestic backlog is the multi-year installation floor. The mix between sales (upfront revenue, lower ongoing share) and JV (lower upfront, ongoing revenue share) is structurally flexible — management has guided that as cash and balance sheet capacity allow, they will lean into JV in high-PSA markets (Japan, Australia, France) where the ongoing box-office capture is more attractive than the upfront sale. Q2's 36 installs put the company on the high end of the raised 150-160 FY25 guide.

FY25 Outlook — Multiple Guidance Raises

The pattern matters: management raised the install guide AND the EBITDA margin guide on a quarter where they did NOT raise the box office guide. The implication is that the operating leverage at any given level of box office is structurally higher than the model previously assumed. Box office at $1.2B is the same target; EBITDA at that level is now ~$185M (assuming the low-40s margin lands at midpoint), implying ~25% growth in adjusted EBITDA vs. 16% revenue growth.

Key Topics & Management Commentary

Overall Management Tone: Confident and forward-leaning, with the CEO treating the FFI step-change as fact rather than aspiration ("the higher level is business as usual"). Defensiveness is reserved for a single topic — the late-Q2 PLF-consortium media report — where the response is bordering on dismissive. The CFO's prepared remarks added specificity to the operating-leverage thesis without overpromising on margin trajectory.

1. Film for IMAX Is a Structural Re-Pricing of the Network

"With all 7 of these films to date, we've averaged about 15% of the North American box office on opening weekend on just 400 IMAX screens, soaring as high as 20% on Mission Impossible - The Final Reckoning, Sinners and F1. That's a feat we've only achieved 8 times in our entire history and 3 of those milestones came in this second quarter. … It's becoming increasingly clear that we're raising the floor for our market share. 10% used to be the high end of what we delivered on major tentpole releases. Now thanks to our film for IMAX strategy, the higher level is business as usual."
— Richard Gelfond, CEO

The 7-FFI-in-a-row summer run is the headline operational achievement of Q2. The economics of indexing 15% of opening-weekend box office on <1% of screens are fundamentally different from the indexing IMAX historically achieved on tentpole releases. Three of those 7 titles hit 20%+ — a feat that took IMAX 25+ years to achieve 8 times previously, and that the company has now matched in 3 months. The 16% indexing on Superman's opening was the highest market share ever on a domestic debut over $100M.

For 2026, IMAX has 9 FFI titles already locked. For 2027, at least 8. The 2 to 5x increase in FFI cadence vs. historical levels is the operational expression of "raising the floor on the indexing."

Assessment: The FFI strategy is the single most important operational development for IMAX in the past decade. It converts what was previously a stochastic "did a blockbuster come out this quarter" model into a structural indexing model where every major release on the calendar has a known IMAX indexing premium attached. The 15-20% opening-weekend indexing on FFI titles is the new base case for major tentpoles, and the FY26/FY27 slate visibility means the run-rate is locked in for years. The competitive moat (filmmaker preference, exclusive aspect ratio, brand) makes the FFI franchise effectively un-replicable by the PLF competition.

2. Operating Leverage Is Real and Quantified

"Exceeding box office levels over $250 million in each quarter, essentially, every dollar beyond that flows right through down to EBITDA and to cash at about an 85% conversion rate. … From a cost basis, when you look at it, we actually don't have a significant increase in costs expected just because the basis of our costs are pretty stable."
— Natasha Fernandes, CFO

The CFO put a specific number on the operating leverage that has historically been articulated qualitatively. Above the $250M quarterly box-office threshold (which Q2 substantially exceeded at $293M; Q3 will exceed if July run-rate holds), incremental dollars of revenue convert to EBITDA at ~85%. That conversion rate explains the +780bp YoY EBITDA margin expansion on +41% box-office growth.

The fixed-cost base — remastering, marketing, SG&A — has been deliberately held flat through OpEx restructuring ($840K of YTD restructuring costs, $3M YoY OpEx decline). This means the margin expansion is structural, not cyclical.

Assessment: The 85% incremental EBITDA conversion above $250M quarterly box office is the most important framework for modeling IMAX going forward. At $325M quarterly box office (where Q3 looks headed given July pacing), incremental EBITDA is ~$64M annualized over the Q2 base. Combined with the network-growth-driven base revenue increase, the model's full-year EBITDA trajectory has visible upside through 2026-2027 even before accounting for the increased FFI cadence.

3. Network Growth Is Geographically Diversifying

"The full year is set to yield several milestones, including our largest single year expansion ever in France with 7 expected installations, 5 of which have already been completed. Our largest single year expansion in the Netherlands with 4 expected installations, close to doubling our network in that country. And our largest single year expansion ever in Japan with 8 already installed and at least 4 to go, representing network growth of over 20% in that country from last year."
— Richard Gelfond, CEO

The 124 YTD signings spread across geographies that historically have been less penetrated for IMAX. Japan is the standout — network growing +20% in a single year, on the back of Demon Slayer-driven local-language indexing. Australia is similar — 6 installs this year vs. a starting base of 2-3 locations, with EVT/Hoyts/Village signings extending the pipeline. France will see its largest single-year expansion ever; Netherlands network will nearly double.

The Wanda agreement to replace existing premium-format auditoriums in up to 27 Chinese locations is the explicit "competitive moat" demonstration — Wanda is choosing IMAX over its own PLF brand or third-party PLFs.

Assessment: The geographic diversification of network growth is a structural risk-reducer for the IMAX investment thesis. Historically, IMAX network growth has been concentrated in a small number of large-exhibitor relationships (AMC domestically, Wanda in China). The breadth of FY25 signings — Japan, Australia, France, Netherlands, Manhattan, L.A. — both broadens the box-office geographic mix and dilutes any single-customer risk. The 2,000-zone TAM (less than 50% penetrated globally per management) is the multi-year runway.

4. The PLF-Consortium Threat Is Mostly Smoke

"A lot of people have tried to create competitors to IMAX over the years, but the fact is that our brand and relationships with filmmakers are unmatched and our technology is superior and audiences know. Two of the three exhibitors mentioned in the story you're referring to have told us that they're not part of any discussions. We just signed a renewal for 40 locations with Regal and are opening new locations with them in L.A. and New York City. And if you miss the boat, it's getting a little late. And I think these are kind of pathetic attempts to try and take a stand that is highly unlikely to work."
— Richard Gelfond, CEO

The mid-July media story flagging "U.S. theater chains in talks about jointly marketing PLF screens to compete with IMAX" briefly pressured the stock. The management response is unusually direct — two of the three named exhibitors have privately confirmed they are not in any such discussions; the third (AMC, IMAX's largest customer) has just signed a new agreement with IMAX. The Regal 40-location renewal and new builds in L.A. and Manhattan close out the rebuttal.

The competitive context: smaller PLF brands have lost share against IMAX as the FFI indexing has expanded. The press story reads as a positioning play by sub-scale operators rather than a credible market structure shift.

Assessment: The PLF-consortium narrative is a positioning artifact, not a competitive threat. The structural moats — filmmaker preference for the IMAX aspect ratio (the only commercially available cameras for FFI shooting), 55-year brand equity, exclusive release windows, expanded aspect ratio in the auditorium — are not replicable by a marketing consortium. We treat this story as the kind of cyclical noise that pressures the stock briefly without changing the multi-year thesis. If anything, the management dismissiveness signals confidence in the moat that is itself a positive signal.

5. Local-Language Strategy Is a Differentiator

"So far this year, our percentage of local language content is around 40%, which is much higher than historically. It's been closer to around 20% in the prior couple of years. … look at like the North American exhibitors, for example, it's close to 0, their percentage for local language content. And I think one of the superpowers of IMAX is our ability to get these films from all over the world."
— Richard Gelfond, CEO

The local-language box office YTD is $230M, just shy of the $244M FY23 full-year record, with the Demon Slayer Japan release scheduled to push the metric past the full-year record within Q3. The 40% local-language mix in 2025 vs. ~20% historical is the structural shift. The IMAX advantage is the global network — North American exhibitors have ~0% local-language box office; IMAX's global footprint makes Japanese animation, Chinese tentpoles, and Indian releases globally accessible.

Ne Zha 2 (Chinese New Year 2025) generated $160M in IMAX alone — the kind of single-title performance that previously required a Hollywood tentpole. The Demon Slayer Japanese release (currently rolling out to 40+ countries) is on pace for a similar global performance trajectory.

Assessment: The local-language strategy is the second-most-important operational development at IMAX (after FFI). It de-risks the slate by diversifying away from Hollywood production cycles, captures revenue in geographies where IMAX's network is growing (Japan, India, China), and is structurally inaccessible to NA-only PLF competitors. The 40% local-language mix is a sustainable run-rate at minimum; we expect it to expand toward 45-50% as the international network grows.

6. The April 2026 Convert Is Being Pre-Emptively De-Risked

"We are also making progress strengthening further our capital structure with a significant announcement last week of our amended and enlarged credit facility, which we expanded from $300 million to $375 million with a term that extends into 2030 and at an approved borrowing rate. … With our strong liquidity position and available facilities, we have the ability to be opportunistic as we assess the timing of when to address these notes and the nature of the instrument, whether that be our revolver or through new notes."
— Natasha Fernandes, CFO

$230M of convertible senior notes mature in April 2026 with a 0.5% coupon and a $37 conversion price. The pre-Q2 narrative had this as the lone capital-structure overhang. The revolver expansion to $375M with maturity to 2030 — done mid-July, before the earnings release — explicitly addresses this. Total available liquidity is now ~$490M against the $230M convert obligation.

Management has three options to address the convert: (1) use the expanded revolver, (2) issue new convertible notes (the 0.5% coupon implies the company has access to attractive convertible-debt markets), or (3) some combination. The CFO's "be opportunistic" language signals they will optimize the refinancing timing against equity-market and convertible-market conditions over the coming 8 months.

Assessment: The capital-structure overhang has been materially de-risked. The cleanest outcome would be a new convertible issue at a higher conversion price than the current $37, capturing the operational re-rate of the past 18 months. Even using the revolver only, the company has the liquidity to retire the convert without dilution. We model the convert refinancing as a non-event for the equity story.

7. Cash Flow Conversion Is Structurally Improving

"Cash flow continues to strengthen. … Our first half operating cash flow was $30 million, it's up 25% year-over-year. Our free cash flow continues to improve as well. We were historically at around 50% and we're trending towards that as well. And as you start to think about just the operating leverage in our model, that's what starts to push through straight down to cash."
— Natasha Fernandes, CFO

1H operating cash flow $30M (+25% YoY). Free cash flow conversion (vs. adjusted EBITDA) is "trending toward 50%" — historically a pre-pandemic benchmark. The 85% incremental EBITDA conversion above $250M quarterly box office translates directly to cash because the underlying joint-revenue-sharing structure front-loads CapEx (at the beginning of the 10-year contract term) and back-loads the cash collection.

1H growth CapEx of $15M is the JRSA-related investment in joint exhibitor partnerships. AMC, Wanda, and Regal are the principal counterparties on this CapEx, which is generating the network growth.

Assessment: The cash flow story is improving in lockstep with EBITDA — not as a separate trajectory. The JRSA structure (front-loaded CapEx, back-loaded box-office share) means the multi-year build is paid for in the high-FCF years that follow. The ~50% FCF/EBITDA conversion target is achievable given the trajectory.

8. The 2H25 Slate Is the Strongest in Years

"This weekend, Marvel's long-awaited Fantastic Four opens worldwide. The Rotten Tomato scores and presales are pretty strong. Our film for IMAX slate continues into the fall with Tron: Ares and Mortal Kombat 2. There are several IMAX-friendly genre releases, including Predator: Badlands and The Running Man. Zootopia 2 is shaping up to be another big sequel for Disney Animation … And the year concludes with the second installment of Wicked and finally, with Avatar: Fire and Ash, which will be proceeded with an IMAX rerelease of Avatar: The Way of Water in October."
— Richard Gelfond, CEO

The Q3 perception is "slate looks soft on paper" — this is the consensus bear point that may briefly pressure the stock. The reality is that Tron: Ares and Mortal Kombat 2 are FFI titles; Predator and Running Man are IMAX-friendly genre titles; Demon Slayer continues its global roll-out; Don J Rescue opens in China in August (FFI release). Q4 is anchored by Wicked and Avatar: Fire and Ash, with the Avatar: The Way of Water re-release in October as a calendar warm-up.

Assessment: The "Q3 slate looks soft" sentiment is a near-term tactical headwind for the stock, not a multi-year thesis risk. The actual Q3 content slate has multiple FFI titles and continues the local-language momentum from Q2. We expect the Q3 print to materially exceed bearish modeling, with the upside surprise concentrated in Demon Slayer's global roll-out and the China local-language slate.

9. 2026 Slate Visibility Is Already Near-Complete

"2026 kicks off the year with the Avatar carryover and features Christopher Nolan's The Odyssey as well as Avengers, Star Wars, the Mandalorian and Grogu, Super Mario Brothers movie sequel, Toy Story 5, Greta Gerwig's Narnia and Dune Part 3 and a very compelling '27 slate continues to take shape, including Star Wars: Starfighter from Deadpool and Wolverine, Director Sean Levy; Avengers: Secret Wars, The Batman 2 and Spider-Man: Beyond the Spider-Verse."
— Richard Gelfond, CEO

The 2026 slate visibility is the deepest in IMAX's history at this lead time. Christopher Nolan's Odyssey (FFI release) sold out IMAX 70mm screenings within 24 hours of tickets being released — a full year in advance. The Mandalorian and Grogu, Dune Part 3, Toy Story 5, Avengers, Narnia (the Netflix collaboration with Greta Gerwig), and the Avatar carryover from Q4 2025 provide multiple tentpole anchors throughout the year.

The Apple-Amazon partnership trajectory continues to deepen. F1 (the Apple film) generated $80M+ in IMAX in Q2 and continues running. Amazon will release its first FFI title — Ryan Gosling's Project Hail Mary — in 2026. Netflix is engaged for Narnia.

Assessment: The 2026 slate visibility is the single most important leading indicator for FY26 box-office estimates. With FFI titles, Hollywood tentpoles, and structural Apple/Amazon/Netflix partnerships all locked in, our base case is that FY26 box office can exceed $1.4B vs. the $1.2B FY25 baseline — a step-function rather than a continuation of the recovery trajectory.

10. SSIMWAVE Streaming Tech Is a Quiet Lever

"We wired, I don't remember exactly the number, it's around 200 theaters, I think a little bit more because that was the way to distribute alternative content. Since we acquired SSIMWAVE using their technology, we came up with an alternative way to deliver alternative content. And that way is by streaming. And it's a much more cost-effective way than wiring it."
— Richard Gelfond, CEO

The 2023 SSIMWAVE acquisition (image-quality monitoring technology) has quietly become the enabling technology for low-CapEx alternative-content distribution. The League of Legends China tournament was delivered via SSIMWAVE-enabled streaming to 150+ theaters with minimal incremental CapEx. The Grateful Dead concert documentary, Prince concert release, and Rolling Stones re-release follow similar streaming-distribution economics.

Alternative content is a low-margin filler vs. tentpole programming, but it carries near-zero capital cost and is a strategic differentiator vs. PLF competitors.

Assessment: The SSIMWAVE-enabled alternative-content strategy is the right way to think about IMAX's content monetization beyond Hollywood/local-language theatrical. It is unlikely to be a material P&L line by itself (management explicitly says it is a filler, not a driver), but it strengthens the differentiation positioning and enables the partnership economics with music, sports, and gaming IP owners.

11. Pricing Discipline Is a Deliberate Choice

"I would say it definitely gives IMAX a stronger hand in our negotiations with the content providers, whether it's studio or live content. But I think we're going to use that carefully. … I think it's a dangerous game to get into kind of different pricing for different movies. I think you send signals that audiences will get that studios want to give -- don't want to give. And I think overall, we think it's a fair result for both the studios and us."
— Richard Gelfond, CEO

An analyst question on whether IMAX could capture more of the box-office split (analogous to hotel-industry royalty rate increases) elicited a deliberate, multi-paragraph "we are going to use that carefully" answer. The CEO's framing: precedent risk, signaling risk, and ecosystem-health considerations argue against monetizing the FFI moat through royalty rate increases. Instead, the moat is being captured through IMAX premieres, marketing co-investment by studios, and filmmaker partnerships.

Assessment: The pricing discipline is structurally bullish. It signals long-term thinking about the IMAX-studio-exhibitor ecosystem; it preserves the optionality to raise rates in future cycles; and it suggests that the +780bp EBITDA margin expansion in Q2 came from operating leverage rather than terms-of-trade renegotiation. This is the right posture for a multi-decade franchise.

Analyst Q&A Highlights

Whether FFI Will Become the Default for All Major Releases

The opening Q&A topic probed whether the success of the 7-FFI summer means IMAX will push to make every blockbuster a Film-for-IMAX release. The management answer was a clear "no" — FFI commitments require a 2-week minimum exclusive window from exhibitors before they have seen the film, and not every IMAX-friendly title justifies that commitment. For 2026, 9 FFI titles are already locked; for 2027, at least 8. The cadence is deliberately controlled to preserve the "this is special" perception.

Q: "Rich, given the strong demand for IMAX slots from studios and filmmakers, do you see a future where all or almost all films you play across your circuit are film for IMAX films? Just curious on how you see the evolution of the number of film for IMAX movies across your network."
— Omar Mejias Santiago, Wells Fargo

A: "I don't think it will evolve to that point, Omar. We want to make film for IMAX something really special, including the right kind of content, the right visual, the right sound. … And as you know, when it's a film for IMAX, it gets a 2-week minimum run. … in 2026, we already have 9 film for IMAX titles. And for 2027, we already have at least 8. So it is something we're going to lean into for the right content, but we won't make it ubiquitous."
— Richard Gelfond, CEO

Assessment: The "won't make it ubiquitous" posture is the right strategic answer — diluting FFI cadence would erase the indexing premium. 9 FFI titles in 2026 vs. 7 in 2H25 represents a controlled 30% increase in cadence, which is consistent with maintaining the indexing while expanding the absolute box-office contribution. This is the management discipline that supports the multi-year thesis.

The PLF Consortium Story and Domestic Exhibitor Relationships

The single most-pressed topic in the call's first 45 minutes — what to make of the late-Q2 media report that U.S. exhibitors are exploring a joint PLF marketing initiative to compete with IMAX. Management's response was unusually direct: two of the three named exhibitors privately disavowed the discussions, AMC just signed a new deal, and Regal just signed for 40 locations and new Manhattan/LA builds. The CEO's language ("pathetic attempts," "good luck with that," "if you miss the boat, it's getting a little late") signaled a confidence not typically used in earnings-call PR responses.

Q: "Maybe switching to some recent media reports that have been stating that U.S. theater chains are under talks about jointly marketing their PLF screens to better compete with the growing influence of IMAX. Do you view this as a competitive threat to your business or more of an opportunity to partner with U.S. exhibitors to potentially work together and grow the pie? Just curious on your thoughts on that."
— Omar Mejias Santiago, Wells Fargo

A: "We've indexed an average of 15% on our FFI films this year on opening weekend and more than 20% on 3 of them. That's a real aha moment for exhibitors who haven't been in the IMAX business before and they're kind of scurrying to come up with a strategy. A lot of people have tried to create competitors to IMAX over the years, but the fact is that our brand and relationships with filmmakers are unmatched and our technology is superior and audiences know. Two of the three exhibitors mentioned in the story you're referring to have told us that they're not part of any discussions. We just signed a renewal for 40 locations with Regal and are opening new locations with them in L.A. and New York City. And if you miss the boat, it's getting a little late."
— Richard Gelfond, CEO

Assessment: The directness of the response is itself the signal. Management would not stake its credibility on private exhibitor conversations being publicly disclosed if those conversations had not actually happened. The PLF-consortium story is a sub-scale-operator marketing pitch, not a competitive threat. The risk we monitor is whether sub-scale PLF operators (e.g., The View in Europe) attempt to win marketing campaigns rather than market share — a tactical nuisance but not a thesis risk.

Pricing Leverage Potential and Hotel-Industry Analogue

An analyst question framed the IMAX situation as analogous to hotel industry royalty rate dynamics — a high-share brand with growing pricing power could capture more of the value chain through rate increases. Management's response was a deliberate, multi-layered "we're going to use that carefully." The pricing decision sits with exhibitors (IMAX does not set ticket prices), but where IMAX could push (taking a higher box-office split) it has chosen not to in favor of marketing co-investment and IMAX premieres.

Q: "I recall from Investor Day several years ago, you laid out the IMAX difference in terms of the economics and the benefits of your partners that would earn your PSAs versus the PSAs they would earn on a non-IMAX screen. … It seems like the results are diverging even further given the indexing and some of the results that you're talking about. So my question is, in the future, could there be opportunities to improve pricing similar to what we see in the hotel industry as they've increased royalty rates, showing their partners that it helps to be with the brand that has bigger scale and marketing benefits?"
— Chad Beynon, Macquarie

A: "I would say it definitely gives IMAX a stronger hand in our negotiations with the content providers, whether it's studio or live content. But I think we're going to use that carefully. … And I think it's a dangerous game to get into kind of different pricing for different movies. … I think we're happy with where the rate is now and we'll use whatever extra negotiating power we might have to try and make the experience better marketed and more accessible for people."
— Richard Gelfond, CEO

Assessment: The pricing discipline is structurally bullish even though it leaves near-term revenue capture on the table. The CEO is signaling that the EBITDA margin expansion is real operating leverage, not extracted margin — which makes the trajectory more durable. The optionality to raise rates in future cycles remains intact.

Local-Language and Alternative Content Mix Evolution

A multi-part question on whether local-language and alternative content will continue to scale at the recent pace. Management's framing: local-language is 40% of YTD box office (vs. ~20% historical) and is here to stay — it is a structural advantage IMAX has over NA-only PLF competitors, and the international network growth is reinforcing the contribution. Alternative content (concerts, sports, gaming) is "important but less of a game changer" — it is filler programming for non-tentpole windows, not a primary growth lever.

Q: "Rich, a big picture question for you. As you think about your ultimate product mix between Hollywood movies, local language, alternative content, like where are you with alternative content in like the number of events that you're doing a year? How are you seeing like the average revenue per event scale higher? Just the opportunities there with those? And where would you like to see the local language percentage be for overall box office as well?"
— Eric Handler, ROTH Capital

A: "So far this year, our percentage of local language content is around 40%, which is much higher than historically. … one of the superpowers of IMAX is our ability to get these films from all over the world. … Alternative content, while important, is less of a game changer and there are a few reasons for that. One is it generally has a shorter playtime. And it also could conflict with studio offerings. … I think we have something like 7 music events coming up in the next few months. … But I just don't think it will have the same financial impact that either the Hollywood slate does do or the local language slate."
— Richard Gelfond, CEO

Assessment: The deliberate framing of alternative content as "filler" rather than a growth driver is the right strategic posture — it allocates management attention to the highest-return programming (FFI tentpoles and local-language blockbusters) and treats alternative content as optionality. The 40% local-language mix is durable at minimum; we expect it to grind toward 45-50% as the international network compounds.

Pricing Sensitivity and the AMC Discount Tuesday Initiative

An analyst question on whether the recent AMC move to expand discount-Tuesday/Wednesday pricing could broaden the IMAX-adjacent moviegoer base by lowering the baseline ticket price. Management's response was a clear "we don't think pricing is the binding constraint" — IMAX consumers have demonstrated willingness to pay a premium for the experience, and the Odyssey ticket pre-sales (selling out a year in advance) are the empirical evidence that the demand curve is not particularly elastic at current prices.

Q: "Do you think moving to lower pricing, if that becomes kind of more the norm midweek across the board, not just with AMC, but with more of your exhibitor partners, does that give more of an incentive to maybe that cohort of moviegoers that may have been more not willing to pay up for IMAX previously and now need more incentive to try out IMAX given that the baseline price is cheaper and maybe the adding on IMAX may be more agreeable to them and maybe you can kind of tap into a moviegoer base that you may not have been able to before and that could be maybe a little bit of a tailwind towards your market share potential kind of moviegoer awareness kind of longer term?"
— Eric Wold, Texas Capital Securities

A: "I think the IMAX consumer over the years has shown that it's willing to pay a premium price for a premium experience. … I just don't think that the premise that lower prices or that … the price we charge is keeping people away. I think people recognize it's a premium experience and they're willing to pay for it. And you look at analogies such as sports ticketing or concert ticketing or other kinds of entertainment. And I think the trends go the other way."
— Richard Gelfond, CEO

Assessment: The IMAX-as-event-pricing framing is consistent with the structural moat — premium experiences command premium pricing without elasticity-driven backlash. The Odyssey 70mm tickets selling out within 24 hours, a year ahead of release, is the most-cited empirical data point. We see no read-across between exhibitor discount-day strategy (which addresses commodity-screen capacity utilization) and the IMAX premium.

2026 Box-Office Growth Confidence and Visibility

A direct question on whether management is confident that 2026 global box office can grow over 2025. Management's response cited the unprecedented forward-slate visibility: Avatar carryover in Q1, FFI titles confirmed at 9, multiple Hollywood tentpoles (Mandalorian, Toy Story 5, Mario, Star Wars, The Odyssey, Avengers, Narnia, Dune Part 3) and "we have a lot of theaters in the backlog as well." The confidence is anchored in slate visibility, not slate-luck modeling.

Q: "Film visibility, Rich, is, I think, probably the best it's ever been for you. Just curious, as we sort of get into the second half of '25, your confidence level that you can grow your GBO in 2026?"
— Michael Hickey, The Benchmark Company

A: "I mean, I have an incredible amount of confidence in that because our '26 slate is almost all filled up. And just some of the high points, we have the Avatar carryover in early '26 and got a number of other good films there, including Project Hail Mary from Amazon MGM. In the second quarter, we've got Super Mario Brothers 2. We've got the new Star Wars, Mandalorian. We've got Toy Story 5, Super Girl in the third quarter. Obviously, the most anticipated one is the Odyssey from Chris Nolan. … So this far in advance, it's unusual to have it virtually all locked in. And then for '27, I think I said this earlier, we not only have a number of films locked in, but we have at least that are film for IMAX films in that. So I would say there hasn't been a point in history where we've had this much locked in 1 and 2 years in advance."
— Richard Gelfond, CEO

Assessment: The slate-visibility framing is the most important forward-looking statement on the call. With 1-2 years of slate locked in, FY26 box office can be modeled bottom-up by title rather than top-down by trend. Our preliminary FY26 base case is $1.4B+ vs. the $1.2B FY25 baseline — a step-function rather than a continuation.

What They're NOT Saying

1. Specific FY26 box-office guide. Management has expressed confidence in FY26 growth but not a number. The next opportunity is likely the Q3 print (October) or an Investor Day if announced.
2. Specific April 2026 convert refinancing structure. Multiple options exist (revolver, new convert, combination); management is being deliberately optionality-preserving. We see this as a positive given the volatile convert market.
3. Specific quantification of the indexing premium economics. Management speaks to "15% on opening weekend" but does not break out per-screen-average premium vs. non-IMAX PLF formats. Investor Day would be the venue.
4. FY26 install guide. Implied trajectory is continued growth from FY25's 150-160, but no specific number. Backlog at 131 domestic (+46%) supports 170+ FY26 base case.
5. Specific share buyback plans. The convert refinancing is the immediate capital-allocation priority; buybacks are not on the agenda for the near term.
6. The exhibitor-tension subplot beyond AMC and Regal. Management addressed the PLF-consortium story head-on but did not detail the broader exhibitor relationships beyond the largest few. The breadth of the network — 257 exhibitor partners globally as of FY24 — suggests a more diversified counterparty set than the story implies.
7. Specific Apple/Amazon/Netflix partnership economics. Management acknowledges the streamer-IMAX dynamic is expanding (F1 with Apple; Project Hail Mary with Amazon; Narnia with Netflix) but does not detail the revenue-share structures. These appear to be premium economics relative to traditional studio releases given the strategic value to the streamers.

Market Reaction

• Pre-print setup: IMAX closed July 23 at ~$28.50. YTD ~+33%; trailing 30-day -2%; trailing 12-month +28%. The trailing 30-day weakness reflected the brief mid-July pressure from the PLF-consortium media story.
• After-hours / next-session move: Stock indicated +3-5% pre-market following the print. Q2 results cleared both the operational and sentiment bars set by the PLF-consortium story.
• Volume: Pre-market volume elevated to ~2x average.
• Peers: AMC, Cinemark, and other theatrical exposure trading sideways to slightly positive — the indexing-premium framing in IMAX's print supports the broader theatrical-recovery narrative without changing exhibitor competitive positioning.

Interpretive read: The market is digesting Q2 as the cleanest confirmation yet that IMAX has structurally inflected. The trailing-30-day weakness was a PLF-consortium-narrative artifact; the print resolves that question definitively. We expect the stock to grind toward $30+ over the coming weeks as Q3 indexing data (Demon Slayer global, Tron: Ares FFI, Don J Rescue China) confirms the FFI/local-language thesis on incremental titles. The next material catalyst is the Q3 print (likely late October), where the Q2-to-date momentum and the August/September FFI titles will set the FY25 box-office finish.

Street Perspective

Debate 1: Is the FFI Indexing Step-Up Sustainable?

Bull view: The 15% opening-weekend indexing (with 20%+ on 3 titles this summer) reflects a structural shift in filmmaker-IMAX collaboration. The cadence is locked in for 2026 (9 FFI titles) and 2027 (8 FFI titles). The economic alignment between IMAX, filmmakers, and studios has structurally tightened — IMAX premieres, marketing co-investment, exclusive aspect-ratio capture, and the "filmmaker-as-evangelist" effect (Coogler with Sinners, Kosinski with F1, Nolan with The Odyssey) compound the indexing.

Bear view: The 15-20% indexing is unusually concentrated in a 7-FFI summer that may not repeat — the H2 25 slate is "soft" by comparison, and 2027 FFI titles are skewed toward IP that may not deliver the same indexing premium (Star Wars: Starfighter, Thomas Crown Affair). The risk is that the 2025 FFI peak overstates the durable indexing run-rate by 200-300bp.

Our take: The structural shift is real, but the 2025 indexing should be modeled as the high end of a sustainable 12-15% indexing range, not the median. Even at the lower end of the range, the FFI program is a meaningful uplift vs. the historical 8-10% indexing on tentpole releases. We expect FY26 indexing to compress modestly (to ~13-14% average) while overall box office grows on slate breadth — a net positive thesis.

Debate 2: Does the China Concentration Risk Threaten the Box-Office Run-Rate?

Bull view: China's local-language slate has matured into a structural contributor (Ne Zha 2 generated $160M in IMAX alone; Don J Rescue opens in August; the Wanda PLF replacement deal adds 27 locations). China's box-office contribution diversifies the overall IMAX revenue base and de-risks Hollywood slate concentration.

Bear view: China's box-office is concentrated in 2-3 mega-titles per year. Q1 2026 will lap Ne Zha 2 — a comp that requires multiple smaller Chinese titles to replicate. The China geopolitical risk (potential further restrictions on Hollywood releases) remains a tail risk. The structural local-language momentum is real, but the quarterly cadence is volatile.

Our take: China is a contribution amplifier, not a structural pillar. The base case for FY26 should not assume a Ne Zha-equivalent title; the contribution beyond the base case is upside. The geopolitical tail risk is monitored but not modeled as base case. Q1 2026 China YoY comparisons will be optically poor, which may create a tactical entry point.

Debate 3: How Quickly Can the April 2026 Convert Be Refinanced and at What Cost?

Bull view: The expanded revolver to $375M with maturity to 2030 provides full liquidity to retire the $230M convert without new convertible issuance. If a new convert is issued, the operational re-rate over the past 18 months supports a conversion price meaningfully above the $37 current. The convert refinancing is operational housekeeping, not a thesis risk.

Bear view: Using the revolver fully would increase debt-to-EBITDA from ~1x to ~1.5x — manageable but not optimal. A new convert at a higher conversion price preserves balance-sheet flexibility but introduces some equity dilution. The mid-2026 refinancing window may coincide with a period of macro volatility.

Our take: The cleanest outcome is a new convert at a higher conversion price (likely $42-48 range based on operational re-rate), preserving balance-sheet flexibility while minimizing dilution. Total dilution risk is modest given the operational trajectory. The refinancing event itself is a near-term overhang but not a multi-quarter risk.

Model Implications & Thesis Scorecard

Model Update

• FY25 estimates: Revenue ~$420M (vs. $352M FY24, +19%); EBITDA ~$175M (low-40s margin); EPS ~$1.40-$1.50
• FY26 estimates: Revenue ~$465M (+11%); EBITDA ~$205M (mid-40s margin); EPS ~$1.65-$1.85
• FY27 estimates: Revenue ~$500-520M (+10%); EBITDA ~$235M (mid-to-high 40s margin); EPS ~$1.90-$2.20
• Long-term framework: High-single-to-low-double-digit revenue CAGR through 2028; operating margin trending toward 50% with peak network leverage; FCF conversion toward 55-60% of EBITDA at maturity

Thesis Scorecard

Rating & Action

Initiating coverage at Outperform. IMAX has structurally inflected. The Film-for-IMAX program has unlocked a new indexing floor (15-20% opening-weekend on <1% of global screens), the multi-year slate visibility is the deepest in company history (2026 "almost all filled," 2027 8 FFI titles confirmed, 2028 slate emerging), the operating leverage above $250M quarterly box office converts incremental dollars to EBITDA at ~85%, and the lone capital-structure overhang (the April 2026 convert) has been pre-emptively de-risked through the revolver expansion. The Q2 print is the cleanest single-quarter confirmation of the operating model in IMAX's recent history.

Fair value range: $32-$40. Stock at ~$28.50 pre-print; expecting 5-8% post-print move toward $30+. The fair-value range reflects (a) FY26 EBITDA of $200M+ at mid-40s margin; (b) ~10-12x EV/EBITDA multiple in line with high-quality premium consumer franchises; (c) modest convert dilution priced in at the high end of the conversion-price range.

What would change our view:

• Upgrade further: A Q3 print materially exceeding the "soft slate" bear narrative; a clean convert refinancing at a conversion price above $42; a 2026 FFI cadence raise to 12+ titles.
• Downgrade to Hold: Q3 indexing compression below 12% on FFI titles (suggesting summer was a slate-luck peak); China local-language slate disruption; convert refinancing executed at a premium reflecting elevated dilution; PLF-consortium narrative gaining traction with multiple credible exhibitor signatories.

Key watch items into Q3 2025 (October 2025):

• Q3 box office performance — particularly indexing on Tron: Ares (FFI), Demon Slayer global, and Don J Rescue China
• Sustainability of 40%+ local-language mix as Demon Slayer rolls into multiple geographies
• Install pace into Q4 — backlog conversion and the path to 150-160 FY25 systems
• Signings momentum — does the 124 YTD trajectory continue toward 175-185 for FY25?
• FY26 slate confirmations and any incremental FFI title announcements
• Capital structure progress — explicit framework for the April 2026 convert
• Stockholder action — buyback authorization or new convert pricing signals
• FY25 guidance updates — particularly whether the EBITDA margin guide gets raised again